

Cancer Molecular Screening and Therapeutics (MoST) Program in Leukaemia and Lymphoma (MoST-LLy)

General Information Sheet


Contact details for queries:

Gerlinda Amor & Helen Christensen- Clinical Trial Project Managers

Email: mostlly@qimrberghofer.edu.au

What is the MoST-LLy Program?

The Molecular Screening and Therapeutics (MoST) Program is a clinical research program that is testing a new approach to providing treatments for patients with cancer. MoST-LLy is a cohort within MoST that is just for patients with blood cancers. The MoST program personalises experimental treatment based on an individual's unique cancer genetic profile, rather than where their cancer originates.



If a patient is suitable for the program, their blood cancer is tested to see if the DNA contains genetic biomarkers that can guide treatment. This process is called molecular screening or genetic testing. After a patient's blood cancer is tested, a report is sent to their referring haematologist with information on (i) any genetic biomarkers that were identified and (ii) the types of treatment that may be suitable.

Who is suitable for the MoST-LLy Program?

- Patients with advanced or poor-prognosis blood cancer of any type
- Patients aged 18 years and over
- Patients with limited treatment options, or who are receiving their last line of standard therapy

How can a patient enrol in the MoST-LLy Program?

- A patient is asked to discuss the program with their treating haematologist.
- If their haematologist thinks the patient meets the eligibility criteria and is suitable for the program, they may refer the patient by filling in the online referral and attaching a pathology report (to confirm patient diagnosis and gain access to samples for testing) to:

<https://smartiq.omico.org.au/produce/wizard/a25f84d1-4be9-4f31-8823-3d16e433498e/>

If you are interested in the program and would like a copy of the eligibility criteria and MoST-LLy referral form, please email Mostlly@qimrberghofer.edu.au